Navigation Links
Echo Therapeutics Announces Third Quarter 2013 Financial Results
Date:11/7/2013

PHILADELPHIA, Nov. 7, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended September 30, 2013. Echo's Quarterly Report on Form 10-Q, when filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.

Recent Corporate Highlights

  • Echo continued to enroll patients in its multi-center clinical trial of its Symphony CGM System in surgical patients in hospital critical care units.  The Company expects to complete the study in the fourth quarter, and will subsequently submit the CE Mark Technical File for marketing approval in Europe.
  • Echo received comments from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health on the pre-submission package that was filed in June 2013. Subsequent to the end of the third quarter, the Company met with the FDA to obtain guidance regarding the regulatory pathway for Symphony. Based on the FDA's comments and Echo's preliminary statistical analysis, the Company believes the FDA Pivotal Trial will have a sample size of 250-350 patients. Echo also plans to submit an Investigational Device Exemption, or IDE, for a Clamping Study to manipulate glucose levels on healthy volunteers to provide the Company with additional data to support its eventual Premarket Approval, or PMA, submission.
  • Robert F. Doman was appointed Echo's Executive Chairman and Interim Chief Executive Officer, effective August 26, 2013.
  • At the end of the third quarter, Echo implemented a number of substantial cost reduction initiatives aimed at reducing operating costs, particularly marketing and manufactur
    '/>"/>

  • SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/6/2015)... 6, 2015  Law office of Brodsky & ... claims against the Board of Directors of Pharmacylics, ... breaches of fiduciary duty and other violations of ... the Company to AbbVie, Inc. ("AbbVie") ... http://brodsky-smith.com/900-pcyc-pharmacyclics-inc.html , or call: 877-534-2590. There is ...
    (Date:3/6/2015)... LAKE FOREST, Ill. , March 6, 2015   ... and the U.S. Food and Drug Administration (FDA) on today,s ... United States . This is a watershed moment for ... medicines. As a leading global provider of biosimilars, Hospira has ... and we are a proud participant in these early stages ...
    (Date:3/6/2015)... 6, 2015  Abaxis, Inc. (NasdaqGS: ABAX ... consumables for the medical, research, and veterinary markets worldwide ... research markets in the United States ... of the U.S. Department of Agriculture (USDA) has cleared ... of   A. phagocytophelium and A. platys ...
    Breaking Medicine Technology:SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Pharmacyclics, Inc. - PCYC 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 2Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 3
    ... SALT LAKE CITY, Feb. 28, 2011 Concentra, a ... is transforming the future of occupational and urgent care ... and engaging experiences for clients and patients. Recent customer ... the ranks of top U.S. consumer companies as a ...
    ... 2011 caprotec bioanalytics GmbH announced today ... of three core patents protecting its proprietary and revolutionary ... CCMS offers a novel and direct way to investigate ... functional reduction of proteome complexity. The core of the ...
    Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology 2
    (Date:3/6/2015)... Ticket Down is a reputable source for authentic ... Moda Center. After being away from the touring business ... signs of letting up on his “Garth Brooks World Tour.” ... Trisha Yearwood, to venues around the United States. The duo ... tour to the Moda Center in Portland, OR. The husband ...
    (Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
    (Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
    (Date:3/6/2015)... 2015 Johnson & Johnson and Ethicon ... March 5, 2015 in Superior Court in the State ... a jury of 12 awarded Mrs. Perry $700,000 in ... with an Ethicon TVT Abbrevo plastic sling for stress ... women also awarded $5 million in punitive damages. , ...
    (Date:3/6/2015)... March 06, 2015 Jvion, the ... release of a Clostridium Difficile (C Diff) predictive ... C Diff use case is the latest in ... hospital acquired infections, chronic conditions, and individual illnesses. ... C Diff solution flags at risk individuals to ...
    Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
    ... UK, has provided new guidelines //for dealing with Post ... psychological therapy be given to victims of PTSD. ... tough. NICE had emphasized that apart from providing food, ... important to give them psychological care to help them ...
    ... created a new breed of mice that can reduce free ... ,The reactive oxygen of the free radicals are known ... health and even death. The new research may be the ... of ageing. ,The new mice created by the ...
    ... will help in medical practitioners to diagnose lupus disease in ... a condition that happens when the body’s tissues are affected ... may produce abnormal antibodies in their blood that may attack ... and virus. This may lead to disease of the lungs, ...
    ... depression may be two separate conditions that frequently co-exist. ... say that it is essential to treat depression and ... ,The researchers had studied 33 women and 20 men ... extensive tenderness to touch along with intense pain and ...
    ... the smoking habit of 6654 people for a period of ... do causes weight gain, but the overall health effect is ... measured for effect of giving up on smoking, gaining weight ... was 20 to 44yrs, and was measured once again for ...
    ... Medicine had been successful in developing an early test ... to finding of neutrophil gelatinase-associated lipocalin (NGAL) as an ... patient had a cardiopulmonary bypass surgery. ,Of the ... children had developed acute renal injury. The amount of ...
    Cached Medicine News:
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
    Steroid-eluting, screw-in pacing lead...
    Medicine Products: